Ser782
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.8
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser782  -  gp130 (human)

Site Information
QVFSRsEsTQPLLDS   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448180

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 4 ) , mass spectrometry ( 1 , 4 ) , mutation of modification site ( 4 ) , peptide sequencing ( 4 ) , phospho-antibody ( 3 )
Disease tissue studied:
HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Phosphatases, in vitro:
PPP2CA (human) ( 3 )
Treatments:
LIF ( 4 ) , MG115 ( 3 ) , okadaic_acid ( 3 ) , phorbol_ester ( 4 ) , tautomycin ( 3 )

Downstream Regulation
Effects of modification on gp130:
protein degradation ( 3 ) , receptor internalization, altered ( 4 ) , receptor recycling, induced ( 2 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Nathanson NM (2012) Regulation of neurokine receptor signaling and trafficking. Neurochem Int 61, 874-8
22306348   Curated Info

3

Mitsuhashi S, et al. (2005) Protein phosphatase type 2A, PP2A, is involved in degradation of gp130. Mol Cell Biochem 269, 183-7
15786731   Curated Info

4

Gibson RM, et al. (2000) Phosphorylation of human gp130 at Ser-782 adjacent to the Di-leucine internalization motif. Effects on expression and signaling. J Biol Chem 275, 22574-82
10811661   Curated Info